It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

AS GLP-1 AGONISTS soar in popularity—about 12 percent of the U.S. population has tried one, most often Ozempic or Wegovy ...

Over half of American adults are eligible for semaglutide, but insurance and other barriers make it hard for people to access ...

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...

A few years ago, West Virginia, which has the highest obesity rate in the nation, quietly began a small and unusual pilot ...

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...